(Q30369681)

21 June 2017

1 reference

title

A decade of innovation in pharmaceutical R&D: the Chorus model. (English)

1 reference

21 June 2017

Paul K Owens

1

1 reference

21 June 2017

Eyas Raddad

2

1 reference

21 June 2017

Jeffrey W Miller

3

1 reference

21 June 2017

John R Stille

4

1 reference

21 June 2017

Kenneth G Olovich

5

1 reference

21 June 2017

Neil V Smith

6

1 reference

21 June 2017

Rosie S Jones

7

1 reference

21 June 2017

Joel C Scherer

8

1 reference

21 June 2017

15 December 2014

1 reference

Nature Reviews Drug Discovery

21 June 2017

1 reference

21 June 2017

14

1 reference

21 June 2017

1

1 reference

21 June 2017

17-28

1 reference

Lessons from 60 years of pharmaceutical innovation

21 June 2017

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

An assessment of R&D productivity in the pharmaceutical industry

31 March 2020

1 reference

The productivity crisis in pharmaceutical R&D.

31 March 2020

1 reference

Diagnosing the decline in pharmaceutical R&D efficiency

31 March 2020

1 reference

Does size matter in R&D productivity? If not, what does?

31 March 2020

1 reference

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

31 March 2020

1 reference

31 March 2020

1 reference

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

31 March 2020

1 reference

Proof of concept: a PhRMA position paper with recommendations for best practice.

31 March 2020

1 reference

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

31 March 2020

1 reference

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial

31 March 2020

1 reference

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

31 March 2020

1 reference

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor

31 March 2020

1 reference

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

31 March 2020

1 reference

Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations

31 March 2020

1 reference

A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer

31 March 2020

1 reference

Spending on new drug development1

31 March 2020

1 reference

Public sector seeks to bridge 'valley of death'

31 March 2020

1 reference

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

31 March 2020

1 reference

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

31 March 2020

1 reference

Minutes of The 43rd General Assembly of The European Association for The Study of Diabetes

31 March 2020

1 reference

Rebuilding the R&D engine in big pharma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25503514

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A more rational approach to new-product development

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25503514

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD4497

1 reference

21 June 2017

1 reference